These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33153146)

  • 41. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
    Janeway KA; Liegl B; Harlow A; Le C; Perez-Atayde A; Kozakewich H; Corless CL; Heinrich MC; Fletcher JA
    Cancer Res; 2007 Oct; 67(19):9084-8. PubMed ID: 17909012
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A quantitative structure-activity relationship study of novel, potent, orally active, selective VEGFR-2 and PDGFRalpha tyrosine kinase inhibitors: derivatives of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}urea as antitumor agents.
    Sharma BK; Sharma SK; Singh P; Sharma S
    J Enzyme Inhib Med Chem; 2008 Apr; 23(2):168-73. PubMed ID: 18343900
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
    Hong JL; Li J; Li J; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future.
    Blay JY; Casali PG; Dei Tos AP; Le Cesne A; Reichardt P
    Oncology; 2015; 89(1):1-13. PubMed ID: 25720422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors.
    Hapkova I; Skarda J; Rouleau C; Thys A; Notarnicola C; Janikova M; Bernex F; Rypka M; Vanderwinden JM; Faure S; Vesely J; de Santa Barbara P
    Exp Mol Pathol; 2013 Apr; 94(2):314-21. PubMed ID: 23295309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation.
    Balasubramanian PK; Balupuri A; Bhujbal SP; Cho SJ
    J Biomol Struct Dyn; 2019 May; 37(8):2165-2178. PubMed ID: 30044205
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current research and treatment for gastrointestinal stromal tumors.
    Lim KT; Tan KY
    World J Gastroenterol; 2017 Jul; 23(27):4856-4866. PubMed ID: 28785140
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In silico research on new sulfonamide derivatives as BRD4 inhibitors targeting acute myeloid leukemia using various computational techniques including 3D-QSAR, HQSAR, molecular docking, ADME/Tox, and molecular dynamics.
    Belghalia E; Ouabane M; El Bahi S; Rehman HM; Sbai A; Lakhlifi T; Bouachrine M
    J Biomol Struct Dyn; 2024 Oct; 42(17):9201-9219. PubMed ID: 37656159
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
    Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
    Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
    Wang WL; Conley A; Reynoso D; Nolden L; Lazar AJ; George S; Trent JC
    Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S15-24. PubMed ID: 21181476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
    Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM
    Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis.
    Ravegnini G; Nannini M; Sammarini G; Astolfi A; Biasco G; Pantaleo MA; Hrelia P; Angelini S
    Int J Mol Sci; 2015 Jul; 16(7):15592-608. PubMed ID: 26184165
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
    Gao J; Li J; Li Y; Li Z; Gong J; Wu J; Liu N; Dong B; Qi C; Li J; Shen L
    Oncotarget; 2016 May; 7(21):30241-9. PubMed ID: 26848617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pathology of gastrointestinal stromal tumors.
    Hirota S; Isozaki K
    Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Gastrointestinal stromal tumors: a rare nosological entity and a model example for the use of personalized therapy with a molecular basis].
    Bettegazzi C; Erra S
    Recenti Prog Med; 2015 Jan; 106(1):52-7. PubMed ID: 25621782
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.
    Hirota S; Ohashi A; Nishida T; Isozaki K; Kinoshita K; Shinomura Y; Kitamura Y
    Gastroenterology; 2003 Sep; 125(3):660-7. PubMed ID: 12949711
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance.
    Srikakulam SK; Bastys T; Kalinina OV
    Proteins; 2020 Nov; 88(11):1434-1446. PubMed ID: 32530065
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
    Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
    Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
    Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; Heslin MJ; Eisenberg B; Birbe R; Patchefsky A; Dunbrack R; Arnoletti JP; von Mehren M; Godwin AK
    Clin Cancer Res; 2005 May; 11(10):3668-77. PubMed ID: 15897563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.